Company intelligence / Profile preview

Solfarcos

Ownership: Private
Employees: ~11
Development stage: Phase 2

Overview

Solfarcos has developed proprietary peptide and protein technologies with successful commercialization in the cosmetic sector. In pharmaceuticals, their lead program—a methotrexate-based liposomal formulation targeting rheumatoid arthritis—completed a successful Phase I trial in September 2021. A proof-of-concept clinical trial was scheduled to begin in the first half of 2022. The company’s revenues are currently driven by B2B sales of cosmetic peptides, with significant reinvestment into R&D.

Therapeutic areas: ImmunologyDermatology
Modalities: PeptidesProteinsLiposomal formulationsRecombinant proteins
Industry: Biotech

Drug pipeline

2 assets

FBL-MTX

1 more asset in the full pipeline.

Request access →

Partnerships

BluepharmaBlueClinical (for RA drug development)University of Minho/Bioprocess & Bionanotechnology Research Group.

Beyond the preview

Go deeper on Solfarcos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solfarcos.

Explore the full profile